Published in Cancer Weekly, November 29th, 2005
In the absence of angiogenesis, tumors cannot establish a sufficient supply of oxygen and nutrients causing tumor cell death and inhibition of tumor growth. Introgen's studies demonstrate that INGN 241 acts as an antiangiogenic agent to inhibit production of a key mediator of angiogenesis called vascular endothelial growth factor (VEGF) protein.
These studies are published in Molecular Therapy and were conducted by researchers at Introgen and...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.